COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted/resubmitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT04002297




Registration number
NCT04002297
Ethics application status
Date submitted
27/06/2019
Date registered
28/06/2019
Date last updated
9/10/2020

Titles & IDs
Public title
Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma
Scientific title
A Phase 3 Randomized, Open-Label, Multicenter Study Comparing Zanubrutinib (BGB-3111) Plus Rituximab Versus Bendamustine Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
Secondary ID [1] 0 0
2019-000413-36
Secondary ID [2] 0 0
BGB-3111-306
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - zanubrutinib
Treatment: Drugs - bendamustine
Treatment: Drugs - rituximab

Experimental: zanubrutinib plus rituximab -

Active Comparator: bendamustine plus rituximab -


Treatment: Drugs: zanubrutinib
Administered as two 80 mg capsules by mouth twice a day

Treatment: Drugs: bendamustine
Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6

Treatment: Drugs: rituximab
Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-free survival (PFS) determined by independent central review
Timepoint [1] 0 0
Up to 7 years
Secondary outcome [1] 0 0
PFS by investigator
Timepoint [1] 0 0
Up to 7 years
Secondary outcome [2] 0 0
Overall response rate (ORR)
Timepoint [2] 0 0
Up to 7 years
Secondary outcome [3] 0 0
Duration of response (DOR)
Timepoint [3] 0 0
Up to 7 years
Secondary outcome [4] 0 0
Overall survival (OS)
Timepoint [4] 0 0
Up to 7 years
Secondary outcome [5] 0 0
Participant-reported outcomes (PROs) as assessed by the EQ-5D-5L questionnaire
Timepoint [5] 0 0
Up to 7 years
Secondary outcome [6] 0 0
PROs as assessed by the EORTC QLQ-C30 questionnaire
Timepoint [6] 0 0
Up to 7 years
Secondary outcome [7] 0 0
Occurrence and severity of treatment-emergent adverse events (safety and tolerability)
Timepoint [7] 0 0
Up to 7 years

Eligibility
Key inclusion criteria
Key

1. = 70 years of age at the time of informed consent, OR 65-69 years of age with
comorbidities precluding autologous stem cell transplantation

2. Histologically confirmed diagnosis of MCL

3. No prior systemic treatments for MCL

4. Measurable disease by CT/MRI

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

6. Adequate marrow and organ function

Key
Minimum age
65 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Known central nervous system involvement by lymphoma

2. Participants for whom the goal of therapy is tumor debulking prior to stem cell
transplant

3. Clinically significant cardiovascular disease

4. History of severe bleeding disorder

5. Unable to swallow capsules or disease significantly affecting gastrointestinal
function

6. Active fungal, bacterial and/or viral infection requiring systemic therapy

7. Requires ongoing treatment with a strong CYP3A inhibitor or inducer

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Flinders Medical Centre - Adelaide
Recruitment hospital [2] 0 0
Monash Medical Centre Clayton - Clayton
Recruitment hospital [3] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [4] 0 0
St. Vincent's Hospital - Darlinghurst
Recruitment hospital [5] 0 0
St. Vincent's Hospital Melbourne - Fitzroy
Recruitment hospital [6] 0 0
Peninsula Private Hospital - Frankston
Recruitment hospital [7] 0 0
Canberra Hospital - Garran
Recruitment hospital [8] 0 0
University Hospital Geelong - Geelong
Recruitment hospital [9] 0 0
Royal Hobart Hospital (RHH) - Hobart
Recruitment hospital [10] 0 0
Royal Perth Hospital - Perth
Recruitment postcode(s) [1] 0 0
5042 - Adelaide
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
2139 - Concord
Recruitment postcode(s) [4] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [5] 0 0
3065 - Fitzroy
Recruitment postcode(s) [6] 0 0
3199 - Frankston
Recruitment postcode(s) [7] 0 0
2605 - Garran
Recruitment postcode(s) [8] 0 0
3220 - Geelong
Recruitment postcode(s) [9] 0 0
7000 - Hobart
Recruitment postcode(s) [10] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Illinois
Country [4] 0 0
United States of America
State/province [4] 0 0
Indiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Kentucky
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Nevada
Country [8] 0 0
United States of America
State/province [8] 0 0
New York
Country [9] 0 0
United States of America
State/province [9] 0 0
Oregon
Country [10] 0 0
United States of America
State/province [10] 0 0
South Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
South Dakota
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
Austria
State/province [14] 0 0
Linz
Country [15] 0 0
Austria
State/province [15] 0 0
Salzburg
Country [16] 0 0
Austria
State/province [16] 0 0
Vienna
Country [17] 0 0
Belgium
State/province [17] 0 0
Namur
Country [18] 0 0
Belgium
State/province [18] 0 0
Brugge
Country [19] 0 0
Belgium
State/province [19] 0 0
Brussel
Country [20] 0 0
Belgium
State/province [20] 0 0
Bruxelles
Country [21] 0 0
Belgium
State/province [21] 0 0
Kortrijk
Country [22] 0 0
Belgium
State/province [22] 0 0
Liege
Country [23] 0 0
Belgium
State/province [23] 0 0
Wilrijk
Country [24] 0 0
China
State/province [24] 0 0
Taiwan
Country [25] 0 0
France
State/province [25] 0 0
Bordeaux
Country [26] 0 0
France
State/province [26] 0 0
Bordeau
Country [27] 0 0
France
State/province [27] 0 0
Brest
Country [28] 0 0
France
State/province [28] 0 0
Grenoble
Country [29] 0 0
France
State/province [29] 0 0
Le Mans
Country [30] 0 0
France
State/province [30] 0 0
Lille
Country [31] 0 0
France
State/province [31] 0 0
Nantes
Country [32] 0 0
France
State/province [32] 0 0
Pierre-Bénite
Country [33] 0 0
France
State/province [33] 0 0
Poitiers
Country [34] 0 0
France
State/province [34] 0 0
Quimper
Country [35] 0 0
France
State/province [35] 0 0
Toulouse
Country [36] 0 0
Italy
State/province [36] 0 0
Bologna
Country [37] 0 0
Italy
State/province [37] 0 0
Novara
Country [38] 0 0
Italy
State/province [38] 0 0
Ravenna
Country [39] 0 0
Italy
State/province [39] 0 0
Siena
Country [40] 0 0
Italy
State/province [40] 0 0
Verona
Country [41] 0 0
New Zealand
State/province [41] 0 0
Christchurch
Country [42] 0 0
New Zealand
State/province [42] 0 0
Tauranga
Country [43] 0 0
Poland
State/province [43] 0 0
Bydgoszcz
Country [44] 0 0
Poland
State/province [44] 0 0
Chorzów
Country [45] 0 0
Poland
State/province [45] 0 0
Gdansk
Country [46] 0 0
Poland
State/province [46] 0 0
Gdynia
Country [47] 0 0
Poland
State/province [47] 0 0
Kraków
Country [48] 0 0
Poland
State/province [48] 0 0
Legnica
Country [49] 0 0
Poland
State/province [49] 0 0
Opole
Country [50] 0 0
Poland
State/province [50] 0 0
Walbrzych
Country [51] 0 0
Poland
State/province [51] 0 0
Warszawa
Country [52] 0 0
Poland
State/province [52] 0 0
Wroclaw
Country [53] 0 0
Poland
State/province [53] 0 0
Lódz
Country [54] 0 0
Spain
State/province [54] 0 0
Barcelona
Country [55] 0 0
Spain
State/province [55] 0 0
Girona
Country [56] 0 0
Spain
State/province [56] 0 0
Madrid
Country [57] 0 0
Spain
State/province [57] 0 0
Málaga
Country [58] 0 0
Spain
State/province [58] 0 0
Sevilla
Country [59] 0 0
Taiwan
State/province [59] 0 0
Tainan
Country [60] 0 0
Taiwan
State/province [60] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
BeiGene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab
versus bendamustine plus rituximab in previously untreated participants with mantle cell
lymphoma (MCL) who are not eligible for stem cell transplantation.
Trial website
https://clinicaltrials.gov/show/NCT04002297
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Alfredo Romano, MD, Ph.D.
Address 0 0
BeiGene
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
BeiGene
Address 0 0
Country 0 0
Phone 0 0
1-877-828-5568
Fax 0 0
Email 0 0
clinicaltrials@beigene.com
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT04002297